August 06, 2016 |
Bristol-Myers Squibb Company stock price fell 16% after its breakthrough cancer drug, Opdivo, failed to slow tumor growth in previously untreated patients with non-small cell lung cancer. The reason why may be a diagnostic test.
Forbes